Edition:
United States

Mesoblast Ltd (MESO.OQ)

MESO.OQ on NASDAQ Stock Exchange Global Select Market

5.54USD
25 Apr 2018
Change (% chg)

$0.05 (+0.91%)
Prev Close
$5.49
Open
$5.53
Day's High
$5.56
Day's Low
$5.44
Volume
5,485
Avg. Vol
14,276
52-wk High
$12.50
52-wk Low
$4.75

Chart for

About

Mesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced... (more)

Overall

Beta: 1.94
Market Cap(Mil.): $536.11
Shares Outstanding(Mil.): 94.65
Dividend: --
Yield (%): --

Financials

  MESO.OQ Industry Sector
P/E (TTM): -- 178.44 32.31
EPS (TTM): -0.85 -- --
ROI: -11.24 -0.73 12.97
ROE: -13.20 -2.77 14.84

BRIEF-Mesoblast ‍Enters $75 Mln Non-Dilutive Credit Facility

* ENTERED US$75 MILLION NON-DILUTIVE, FOUR-YEAR CREDIT FACILITY WITH HERCULES CAPITAL

Mar 06 2018

BRIEF-Mesoblast Posts ‍Qtrly Profit Attributable Of $13.7 Mln

* ‍QTRLY PROFIT ATTRIBUTABLE $13.7 MILLION VERSUS LOSS OF $20.1 MILLION ​ Source text for Eikon: Further company coverage:

Feb 27 2018

BRIEF-Mesoblast Says ‍Primary Endpoint Achieved In A Phase 3 Cell Therapy Trial

* ‍PRIMARY ENDPOINT SUCCESSFULLY ACHIEVED IN MESOBLAST'S PHASE 3 CELL THERAPY TRIAL FOR ACUTE GRAFT VERSUS HOST DISEASE​ Source text for Eikon: Further company coverage: (bangalore.newsroom@thomsonreuters.com)

Feb 21 2018

Mesoblast stem cell therapy meets goal of pediatric Graft vs. Host study

Nearly 70 percent of children with potentially fatal acute Graft Versus Host Disease responded to treatment with an experimental stem cell therapy from Mesoblast Ltd, meeting the primary goal of a late-stage U.S. trial, the Australian company announced on Wednesday.

Feb 21 2018

Mesoblast stem cell therapy meets goal of pediatric Graft vs Host study

Feb 21 Nearly 70 percent of children with potentially fatal acute Graft Versus Host Disease responded to treatment with an experimental stem cell therapy from Mesoblast Ltd, meeting the primary goal of a late-stage U.S. trial, the Australian company announced on Wednesday.

Feb 21 2018

FDA to fast track Mesoblast's cell therapy for heart failure

Australian drug developer Mesoblast Ltd said on Thursday the U.S. Food and Drug Administration would fast track the review of its cell therapy treatment for heart failure patients under a new designation rolled out last December.

Dec 21 2017

FDA to fast track Mesoblast's cell therapy for heart failure

Dec 21 Australian drug developer Mesoblast Ltd said on Thursday the U.S. Food and Drug Administration would fast track the review of its cell therapy treatment for heart failure patients under a new designation rolled out last December.

Dec 20 2017

BRIEF-Mesoblast Gets Regenerative Medicine Advanced Therapy Designation From U.S. FDA​

* ‍U.S. FDA GRANTED REGENERATIVE MEDICINE ADVANCED THERAPY DESIGNATION FOR ITS MESENCHYMAL PRECURSOR CELL THERAPY ​ Source text for Eikon: Further company coverage:

Dec 20 2017

BRIEF-Mesoblast's Phase 3 Trial In Children With Acute Graft Versus Host Disease Completes Enrollment

* MESOBLAST'S PHASE 3 TRIAL IN CHILDREN WITH ACUTE GRAFT VERSUS HOST DISEASE COMPLETES ENROLLMENT

Dec 20 2017

BRIEF-Mesoblast Says Granted Tigenix Access To Certain Of Its Patents

* ‍HAS GRANTED TIGENIX EXCLUSIVE ACCESS TO CERTAIN OF ITS PATENTS TO SUPPORT GLOBAL COMMERCIALIZATION OF STEM CELL PRODUCT CX601​ Source text for Eikon: Further company coverage:

Dec 14 2017

Earnings vs. Estimates